Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced a new development and licensing agreement with an established global company in the life sciences and diagnostics sector, part of a major multinational conglomerate.

Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC) assays and diagnostic kits, leveraging its proprietary Optimer®-Fc platform, which produces aptamer binders with an antibody Fc-tag optimised for IHC workflows. The Partner will fully fund the development work, which is expected to be completed within a 12-month timeline, for an undisclosed sum. Subject to development and validation, the Optimer®-Fc reagent is anticipated to be incorporated into commercial IHC kits, with a product launch expected within the current calendar year.

The agreement includes a commercial licensing arrangement, under which Aptamer will receive royalties of 2% on net sales of all assay kits containing the licensed Optimer®-Fc reagent, subject to standard minimum royalty commitments. The kits are expected to be distributed through recognised global channels specialising in life sciences research products.

This partnership strengthens Aptamer’s recurring revenue potential and supports its strategy to expand the application of its Optimer platform in high-value life sciences markets. The collaboration with a globally respected industry leader underscores the commercial potential and technical capabilities of Aptamer’s Optimer®-Fc technology for advanced diagnostic applications.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:

“We are pleased to collaborate with a leading global life sciences company to develop this Optimer®-Fc reagent for IHC applications. The royalty structure and fully funded development provide a clear path to revenue generation and validate the strength of our Optimer platform. This agreement enhances our portfolio of royalty-generating assets and supports our mission to deliver innovative solutions to the life sciences industry.”

Certain details of the agreement, including specific financial terms and the identity of the Partner, are commercially sensitive and have not been disclosed at this stage. The Company will provide updates on material developments as appropriate.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform,

    Search

    Search